Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
BMPR2 encodes a member of the bone morphogenetic protein (BMP) receptor family of transmembrane serine/threonine kinases. Additionally we are shipping BMPR2 Kits (27) and BMPR2 Proteins (18) and many more products for this protein.
Showing 10 out of 129 products:
Human Polyclonal BMPR2 Primary Antibody for FACS, IHC (p) - ABIN388741
Pouliot, Blais, Labrie: Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells. in Cancer research 2003
Show all 9 references for ABIN388741
Human Polyclonal BMPR2 Primary Antibody for FACS, IHC - ABIN4899943
He, Dong, Wang, Xu, Dai, Ma, Zhu: Bone morphogenetic protein receptor IB as a marker for enrichment of osteogenic precursor-like cells in human dermis. in Archives of dermatological research 2011
Show all 3 references for ABIN4899943
Human Monoclonal BMPR2 Primary Antibody for IF, WB - ABIN968806
, Lane, Machado, Pauciulo, Thomson, Phillips, Loyd, Nichols, Trembath: Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. in Nature genetics 2000
Show all 3 references for ABIN968806
Human Monoclonal BMPR2 Primary Antibody for IHC, ELISA - ABIN968987
Rosenzweig, Morse, Knowles, Chada, Khan, Roberts, McElroy, Juskiw, Mallory, Rich, Diamond, Barst: Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2008
Show all 2 references for ABIN968987
Human Monoclonal BMPR2 Primary Antibody for EIA, IF - ABIN1105549
Phillips, Poling, Phillips, Stanton, Austin, Cogan, Wheeler, Yu, Newman, Dietz, Loyd: Synergistic heterozygosity for TGFbeta1 SNPs and BMPR2 mutations modulates the age at diagnosis and penetrance of familial pulmonary arterial hypertension. in Genetics in medicine : official journal of the American College of Medical Genetics 2008
Show all 2 references for ABIN1105549
bmpr2b mediates BMP signaling and is required to establish left-right asymmetry.
The genetic-interactions among BMPR-2, ALK-1 (show ACVRL1 Antibodies), and 5-HTT (show SLC6A4 Antibodies) polymorphisms, elevated BMP-2 (show BMP2 Antibodies) and 5-HT (show DDC Antibodies) levels and differential gene expression substantiated the strong genetic contribution in high altitude pulmonary edema pathophysiology.
Patients with pulmonary arterial hypertension and bone morphogenetic protein receptor type II mutations present at a younger age with more severe disease, and are at increased risk of death, and death or transplantation, compared with those without BMPR2 mutations.
Study of four patients with pulmonary arterial hypertension associated with human immunodeficiency virus infection found predisposing mutations in the BMPR2, ACVRL1 (show ACVRL1 Antibodies) and ENG (show ENG Antibodies) genes.
BMPR2 mutations were identified in congenital heart disease-pulmonary vascular disease patients, with missense mutation of BMPR2 as the dominant mutation type.
his study demonstrated that both rs6435156C > T and rs1048829G > T variants in BMPR2 contributed to increased susceptibility to hronic obstructive pulmonary disease
Increased HMGA1 (show HMGA1 Antibodies) in pulmonary arterial endothelial cells resulting from dysfunctional BMPR2 signaling can transition endothelium to smooth muscle-like cells associated with pulmonary arterial hypertension.
Pulmonary arterial hypertension patients carrying a BMPR2 mutation have decreased right ventricular function compared to patients without the mutation.
the data in the present study support the notion that the expression levels and plasma membrane levels of BMPRII are determined by two molecular processes-translational regulation of protein synthesis (which provides the major contribution) and endocytosis/degradation (mild modulatory effect).
In a group of pulmonary arterial hypertension patients, 25.4% harboured heterozygous mutation in the BMPR2 gene.
An up-regulated expression of BMP-4 (show BMP4 Antibodies) and BMPR-II was observed in the peripheral blood of breast cancer patients especially in the advanced-stage of the disease. Moreover, BMP-4 (show BMP4 Antibodies) and BMPR-II expressions were found to be correlated
BMPR2 gene transfer reduced TGF-beta (show TGFB1 Antibodies) effects on Smad2 (show SMAD2 Antibodies), Smad1 (show SMAD1 Antibodies)/5/8 and Erk1/2 (show MAPK1/3 Antibodies) phosphorylation in human pulmonary arterial smooth muscle cells
Deleting Bmpr2 in mouse skeletal progenitor cells impaired activin (show Actbeta Antibodies) signaling resulting in an increased bone formation rate and high bone mass.
The findings suggest that the mutant ALK2 (show ACRV1 Antibodies) related to Fibrodysplasia ossificans progressiva is enhanced by bone morphogenetic protein type II receptors via the T203-regulated phosphorylation of ALK2 (show ACRV1 Antibodies).
BMPR2 has tumor suppressive functions in the stroma by regulating inflammation.
Serotonin can increase ERalpha (show ESR1 Antibodies) expression in human pulmonary arterial smooth muscle cells and antagonism of oestrogen receptor alpha reverses serotonin-dependent PH in the mouse and increases bone morphogenetic protein receptor type 2 expression
BMPR2 preserves mitochondrial function and DNA during reoxygenation to promote endothelial cell survival and reverse pulmonary hypertension.
Members of the miR-17 family influence gastrulation by suppressing Bmpr2 expression at the primitive streak.
Bmp4 (show BMP4 Antibodies), Bmp7 (show BMP7 Antibodies) and bmpr2 signalling regulates the pre-implantation development of extra-embryonic cell lineages in the mouse embryo
Mutations in BMPR2 underlie most heritable cases and a small proportion of sporadic cases of idiopathic pulmonary arterial hypertension.
BMP9 (show GDF2 Antibodies) is identified as the preferred ligand for preventing apoptosis and enhancing monolayer integrity in endothelial cells from subjects with pulmonary arterial hypertension who bear mutations in the gene encoding BMPR2.
Report temporal regulation of BMPR2 mRNA expression in the oocyte, granulosa and theca cells of developing preovulatory follicles in the pig.
Losartan therapy was associated with persistent overexpressions of ANG II (show AGT Antibodies), AT2 (show AGTR2 Antibodies), ET-1 (show EDN1 Antibodies), ETB (show EDNRB Antibodies), and angiopoietin-1 (show ANGPT1 Antibodies) and with a return to normal of the BMPR-2 expression.
Stimulation of BMPRII promotes normal pulmonary artery endothelial cell function by activating eNOS (show NOS3 Antibodies).
This gene encodes a member of the bone morphogenetic protein (BMP) receptor family of transmembrane serine/threonine kinases. The ligands of this receptor are BMPs, which are members of the TGF-beta superfamily. BMPs are involved in endochondral bone formation and embryogenesis. These proteins transduce their signals through the formation of heteromeric complexes of two different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding. Mutations in this gene have been associated with primary pulmonary hypertension, both familial and fenfluramine-associated, and with pulmonary venoocclusive disease.
bone morphogenetic protein receptor type II
, bone morphogenetic protein receptor type-2
, bone morphogenetic protein receptor type II b
, BMP type II receptor
, BMP type-2 receptor
, type II activin receptor-like kinase
, type II receptor for bone morphogenetic protein-4
, bone morphogenic protein receptor, type II (serine/threonine kinase)
, bone morphogenic protein receptor type 2